These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 18454052)

  • 41. Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer.
    Kanai M; Matsumoto S; Nishimura T; Shimada Y; Watanabe G; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Teramukai S; Mitsumori M; Chiba T; Sakai Y; Fukushima M
    Int J Clin Oncol; 2007 Jun; 12(3):224-7. PubMed ID: 17566847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance.
    Toi M; Saeki T; Iwata H; Inoue K; Tokuda Y; Sato Y; Ito Y; Aogi K; Takatsuka Y; Arioka H
    Breast Cancer; 2014 Jan; 21(1):20-7. PubMed ID: 22382811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First-line chemotherapy of advanced breast cancer with a combination of mitoxantrone, methotrexate, and vincristine (MIMO).
    Samonis G; Bafaloukos D; Margioris AN; Katsarma G; Toloudis P; Bacoyannis C; Karvounis N; Georgoulias V; Kosmidis P
    Oncology; 1997; 54(5):371-5. PubMed ID: 9260597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Timed-flat infusion of 5-fluorouracil associated with docetaxel as first-line treatment of patients with metastatic breast cancer.
    Rispoli AI; Morelli MF; Ricevuto E; Cannita K; Santomaggio A; Mancini M; Tudini M; Cianci G; Porzio G; Lanfiuti Baldi P; Di Rocco CZ; Tinari N; Iacobelli S; Marchetti P; Ficorella C
    Breast J; 2008; 14(1):116-7. PubMed ID: 18086273
    [No Abstract]   [Full Text] [Related]  

  • 45. A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.
    König E; Kurbacher C; Schwonzen M; Breidenbach M; Mallmann P
    Anticancer Drugs; 2002 Sep; 13(8):827-32. PubMed ID: 12394267
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Multicenter Study of Docetaxel at a Dose of 100 mg/m
    Hirata T; Ozaki S; Tabata M; Iwamoto T; Hinotsu S; Hamada A; Motoki T; Nogami T; Shien T; Taira N; Matsuoka J; Doihara H
    Intern Med; 2021 Apr; 60(8):1183-1190. PubMed ID: 33191320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two-weekly docetaxel in treatment of advanced breast cancer: A preliminary study.
    Lee DW; Kang IH; Ismail F
    Med J Malaysia; 2020 Jul; 75(4):338-341. PubMed ID: 32723991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    van Eijk M; Vermunt MAC; van Werkhoven E; Wilthagen EA; Huitema ADR; Beijnen JH
    BMC Cancer; 2022 Jan; 22(1):104. PubMed ID: 35078455
    [